Risk factors for loss of virological suppression in patients receiving lopinavir/ritonavir monotherapy for maintenance of HIV suppression

Federico Pulido(Bellvitge University Hospital), José Ramón Arribas(Hospital Universitario La Paz), Rafael Rubio(Research Institute Hospital 12 de Octubre), Antonio Ocampo(University Hospital Complex Of Vigo), Bonaventura Clotet(Universitat de Vic - Universitat Central de Catalunya), Asunción Hernando(Universidad de Alcalá), Marı́a Jesús Pérez-Elı́as(Hospital Universitario Ramón y Cajal), Rafaël Delgado(University of Vassouras), Joaquín Portilla(Hospital General Universitario de Alicante Doctor Balmis), Ignacio Valero(Instituto de Salud Carlos III), Juan Pasquau(Hospital Universitario Virgen de las Nieves), Juan González‐García(Hospital Universitario La Paz), Daniel Podzamczer(Bellvitge University Hospital), Pilar Miralles(Hospital General Universitario Gregorio Marañón), Alberto Arranz(Hospital Universitario Príncipe de Asturias), Vicente Estrada(Instituto de Salud Carlos III)
Antiviral Therapy
February 1, 2009
10.1177/135965350901400210
Cited by 60

Related Papers

Sexual Activity Without Condoms and Risk of HIV Transmission in Serodifferent Couples When the HIV-Positive Partner Is Using Suppressive Antiretroviral Therapy
|JAMA|2016|1.4k
Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study
|The Lancet|2019|1k
Tenofovir DF, Emtricitabine, and Efavirenz vs. Zidovudine, Lamivudine, and Efavirenz for HIV
|New England Journal of Medicine|2006|886
Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19
|JAMA|2021|728
Efficacy of Enfuvirtide in Patients Infected with Drug-Resistant HIV-1 in Europe and Australia
|New England Journal of Medicine|2003|653